Home > Insider Trading > Filing (0001104659-16-153449)

Filing Details

Accession Number:: 0001104659-16-153449
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-10-31 20:46:44
Reporting Period:: 2016-10-31

Filing Date:: 2016-10-31
Accepted Time:: 2016-10-31 20:46:44
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1481512	Ra Pharmaceuticals Inc.	RARX	Pharmaceutical Preparations (2834)	262908274

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1619841	M. Rajeev Shah	C/O Ra Capital Management, Llc 20 Park Plaza, Suite 1200 Boston MA 02116		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-10-31	616,646	$0.00	616,646	No	4	C	Indirect	See footnotes
Common Stock	Acquisiton	2016-10-31	573,624	$0.00	1,190,270	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2016-10-31	161,538	$13.00	1,351,808	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See footnotes
No	4	C	Indirect	See footnote
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B-1 Preferred Stock	Disposition	2016-10-31	4,316,531	$0.00	616,646	$0.00
Common Stock	Series B-2 Preferred Stock	Disposition	2016-10-31	4,015,378	$0.00	573,624	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

These securities include 507,500 shares held by RA Capital Healthcare Fund, L.P. (the "Fund") and 109,146 shares held in an account owned by Blackwell Partners LLC-Series A (the "Blackwell Account").
RA Capital Management, LLC (the "Adviser") is the general partner of the Fund and the investment adviser of the Blackwell Account. Peter Kolchinsky is the sole manager of the Adviser, and Mr. Shah is a managing director of the Adviser. Mr. Shah has no pecuniary interest in the reported securities held in the Blackwell Account and therefore disclaims beneficial ownership of those securities. Mr. Shah disclaims beneficial ownership of the reported securities held by the Fund except to the extent of his pecuniary interest therein.
These securities include 472,093 shares held by the Fund and 101,531 shares held in the Blackwell Account.
Each share of the Series B-1 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically upon the closing of the Issuer's initial public offering, and had no expiration date.
Each share of the Series B-2 Preferred Stock converted into Common Stock on a 1-for-7 basis automatically upon the closing of the Issuer's initial public offering, and had no expiration date.
These securities include 132,357 shares held by the Fund and 29,181 shares held in the Blackwell Account.
These securities include 1,111,950 shares held by the Fund and 239,858 shares held in the Blackwell Account.
These securities include 3,552,506 shares held by the Fund and 764,025 shares held in the Blackwell Account.
These securities include 3,304,656 shares held by the Fund and 710,722 shares held in the Blackwell Account.